Insights and Resources

5 things to know in life sciences: Week of June 3, 2024

REAL ECONOMY BLOG | June 07, 2024

Authored by RSM US LLP

Each week we highlight five things affecting the life sciences industry. Here’s the latest.

Biopharma research productivity increases

  • Recent advancements in artificial intelligence are significantly enhancing research and development productivity by streamlining drug discovery processes, leading to more efficient development of new treatments.
  • Per CHEManager, global biopharma research and development saw improved success rates and increased funding in 2023, driven by innovative trial designs and regulatory acceptance of data-driven methodologies.

Implications of Chevron’s demise for medtech

  • The potential Supreme Court ruling on Chevron deference, a principle that compels courts to defer to a federal agency’s interpretation of ambiguous laws, could profoundly impact medtech regulation, with agency decisions subject to increased legal challenges.
  • Per AdvaMed, eliminating Chevron deference may offer opportunities to contest overreaching regulations but also risk reduced regulatory certainty, impacting innovation and patient access.

BIOSECURE Act and its impact on U.S. biopharma

  • The BIOSECURE Act aims to prevent U.S. federal funding from supporting biopharmaceutical collaborations with certain Chinese companies, potentially affecting over 120 drugs in development.
  • Per Pharmaceutical Technology, this legislation could lead to increased costs and regulatory challenges for U.S. companies, especially those in clinical-stage trials as they seek alternative partnerships and suppliers.

Economic pressures prolong drug shortages, says U.S. Pharmacopeia report

  • Drug shortages in the U.S. are lasting longer due to economic pressures such as low prices, manufacturing complexities and geographic concentration, according to a report by U.S. Pharmacopeia.
  • Fierce Pharma reports that the profitability issues, particularly affecting generic drugs, and quality concerns leading to facility shutdowns, have exacerbated supply chain vulnerabilities, with shortages now averaging over three years in duration.

AI model predicts immunotherapy responses

  • Researchers at the National Institutes of Health and Memorial Sloan Kettering have developed an AI model named LORIS to predict patient responses to immunotherapy using routine clinical data.
  • Per Fierce Biotech, this model, incorporating data from over 3,700 patients, aims to enhance the precision of immunotherapy treatments by identifying likely responders and forecasting survival outcomes.

Let's Talk!

Call us at +1 213.873.1700, email us at or fill out the form below and we'll contact you to discuss your specific situation.

  • Topic Name:
  • Should be Empty:

This article was written by Amanda Laskey, Brian Winne and originally appeared on 2024-06-07. Reprinted with permission from RSM US LLP.
© 2024 RSM US LLP. All rights reserved.

RSM US LLP is a limited liability partnership and the U.S. member firm of RSM International, a global network of independent assurance, tax and consulting firms. The member firms of RSM International collaborate to provide services to global clients, but are separate and distinct legal entities that cannot obligate each other. Each member firm is responsible only for its own acts and omissions, and not those of any other party. Visit for more information regarding RSM US LLP and RSM International.

RSM US Alliance provides its members with access to resources of RSM US LLP. RSM US Alliance member firms are separate and independent businesses and legal entities that are responsible for their own acts and omissions, and each is separate and independent from RSM US LLP. RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Members of RSM US Alliance have access to RSM International resources through RSM US LLP but are not member firms of RSM International. Visit us for more information regarding RSM US LLP and RSM International. The RSM logo is used under license by RSM US LLP. RSM US Alliance products and services are proprietary to RSM US LLP.

​Vasquez & Company LLP is a proud member of the RSM US Alliance, a premier affiliation of independent accounting and consulting firms in the United States. RSM US Alliance provides our firm with access to resources of RSM US LLP, the leading provider of audit, tax and consulting services focused on the middle market. RSM US LLP is a licensed CPA firm and the U.S. member of RSM International, a global network of independent audit, tax and consulting firms with more than 43,000 people in over 120 countries.

Our membership in RSM US Alliance has elevated our capabilities in the marketplace, helping to differentiate our firm from the competition while allowing us to maintain our independence and entrepreneurial culture. We have access to a valuable peer network of like-sized firms as well as a broad range of tools, expertise and technical resources.

For more information on how ​Vasquez & Company LLP can assist you, please call +1 213.873.1700.